Shionogi would like to share an important update about the adolescent open-label extension portion of the zatolmilast trial. Following a comprehensive review and analysis of the data, it was determined that the efficacy measures utilized did not detect a positive treatment signal in the adolescent trial, therefore they are closing the open-label extension of the adolescent trial (17 and under) only.
Read the letter from Chief Medical Officer, Juan Carlos Gomez, who explains the details:
We know this is hard news. Please reach out to us; we’re here to listen and to help. Our deepest thanks to all the families who participated in this trial and continue to participate in trials.
